Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Candida auris
is an emerging fungal pathogen that exhibits resistance to multiple drugs, including the most commonly prescribed antifungal, fluconazole. Here, we use a combinatorial screening approach to identify a
bis
-benzodioxolylindolinone (azoffluxin) that synergizes with fluconazole against
C. auris
. Azoffluxin enhances fluconazole activity through the inhibition of efflux pump Cdr1, thus increasing intracellular fluconazole levels. This activity is conserved across most
C. auris
clades, with the exception of clade III. Azoffluxin also inhibits efflux in highly azole-resistant strains of
Candida albicans
, another human fungal pathogen, increasing their susceptibility to fluconazole. Furthermore, azoffluxin enhances fluconazole activity in mice infected with
C. auris
, reducing fungal burden. Our findings suggest that pharmacologically targeting Cdr1 in combination with azoles may be an effective strategy to control infection caused by azole-resistant isolates of
C. auris
.
The fungal pathogen
Candida auris
is resistant to multiple drugs including the common antifungal fluconazole. Here, Iyer et al. identify a compound that potentiates fluconazole activity against
C. auris
in vitro and in vivo by inhibiting a major efflux pump and thus increasing intracellular fluconazole accumulation.